Johnson & Johnson (NYSE:JNJ) Shares Sold by Shikiar Asset Management Inc.

Shikiar Asset Management Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% during the 1st quarter, Holdings Channel.com reports. The fund owned 2,563 shares of the company’s stock after selling 100 shares during the period. Shikiar Asset Management Inc.’s holdings in Johnson & Johnson were worth $425,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.2%

Shares of NYSE:JNJ opened at $155.24 on Tuesday. The stock has a market capitalization of $373.52 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a 50 day moving average price of $153.96 and a 200 day moving average price of $153.70.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Raymond James lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Finally, Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.